SVB Leerink Initiates Coverage On ContraFect with Outperform Rating, Announces Price Target of $14
SVB Leerink analyst Roanna Ruiz initiates coverage on ContraFect (NASDAQ:CFRX) with a Outperform rating and announces Price Target of $14.
The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 18)
Stocks That Hit 52-Week Lows On Wednesday
Wednesday morning, 136 companies reached new 52-week lows.
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios’ Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 17)
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 16)
ContraFect Q2 EPS $(0.14) Up From $(0.88) YoY
ContraFect (NASDAQ:CFRX) reported quarterly losses of $(0.14) per share. This is a 84.09 percent increase over losses of $(0.88) per share from the same period last year.
UPDATE: ContraFect Posts Presentation For European Congress Of Clinical Microbiology, Infectious Diseases Segment ‘Synergistic anti-biofilm activity of exebacase and rifampin, vancomycin or daptomycin against Staphylococcus…’
https://d1io3yog0oux5.cloudfront.net/_e99d99d56a6747b57991587db6aa722f/contrafect/db/226/1410/pdf/2021_Synergistic+Anti-biofilm+Activity+of+Exebacase_Lyon+ECCMID+2021.pdf
ContraFect Highlights Publications On CF-296
ContraFect Corporation (NASDAQ:CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical